A phase II trial led by University of Michigan researchers found that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control.
University of Michigan Health Rogel Cancer Center received a $50 million gift from Richard and Susan Rogel for pancreatic cancer research and care.
